# Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

> **NCT00003603** · PHASE3 · UNKNOWN · sponsor: **Riverside Haematology Group** · enrollment: 660 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** idarubicin
- **DRUG:** lomustine
- **DRUG:** melphalan
- **DRUG:** prednisolone

## Key facts

- **NCT ID:** NCT00003603
- **Lead sponsor:** Riverside Haematology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003603, "Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00003603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*